Stalfort John A III
SEC CIK 1709418 · EDGAR
BoughtSold
Most active insiders at ABOS, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Meisner Derek M | CLO, Corp Sec | — | $248.8K |
| 2 | OConnell Daniel Joseph | CEO, Dir | — | $163.2K |
| 3 | Porter Derrell | Dir | — | $75.2K |
| 4 | Zuga Matt | CFO, Chief Business Off | — | $49.6K |
| 5 | Barton Russell | COO | — | $30.0K |
| 6 | Siemers Eric | Chief Medical Off | — | $27.1K |
| 7 | Doherty James J. | Pres, CDO | — | $15.2K |
| 8 | Fountain Nathan B | Dir | — | $14.3K |
| 9 | Schacterle Amy | Chief Regulatory Off | — | $2,172 |
| 10 | Stoppel Laura | Dir | — | — |
| 11 | Stalfort John A III | Dir | — | — |
Transactions 14
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-06-05 16:30 | 2026-06-03 | ABOS | Acumen Pharmaceuticals, Inc. | Stalfort John A III | Dir | A - Grant | $0.00 | +35.5K | 220.6K | +19% | $0 |
| D | 2026-06-02 16:30 | 2026-06-01 | TSHA | Taysha Gene Therapies, Inc. | Stalfort John A III | Dir | A - Grant | $0.00 | +21.3K | 1.18M | +2% | $0 |
| D | 2025-06-05 | 2025-06-04 | ABOS | Acumen Pharmaceuticals, Inc. | Stalfort John A III | Dir | A - Grant | $0.00 | +12.8K | 185.1K | +7% | $0 |
| D | 2025-06-04 | 2025-06-02 | TSHA | Taysha Gene Therapies, Inc. | Stalfort John A III | Dir | A - Grant | $0.00 | +56.6K | 1.16M | +5% | $0 |
| D | 2024-11-26 | 2024-11-26 | VRCA | Verrica Pharmaceuticals Inc. | Stalfort John A III | Dir | G - Gift | $0.00 | +50.0K | 1.87M | +3% | $0 |
| D | 2024-11-26 | 2024-11-22 | VRCA | Verrica Pharmaceuticals Inc. | Stalfort John A III | Dir | P - Purchase | — | +1.12M | 1.82M | +160% | — |
| D | 2024-05-31 | 2024-05-29 | TSHA | Taysha Gene Therapies, Inc. | Stalfort John A III | Dir | A - Grant | $0.00 | +49.2K | 1.10M | +5% | $0 |
| I | 2023-08-16 | 2023-08-16 | TSHA | Taysha Gene Therapies, Inc. | Stalfort John A III | Dir | P - Purchase | $0.9 | +388.9K | 884.3K | +78% | +$350.0K |
| 2023-08-16 | 2023-08-16 | TSHA | Taysha Gene Therapies, Inc. | Stalfort John A III | Dir | P - Purchase | $0.9 | +388.9K | 999.4K | +64% | +$350.0K | |
| 2023-08-16 | 2023-08-16 | TSHA | Taysha Gene Therapies, Inc. | Stalfort John A III | Dir | G - Gift | $0.00 | +50.0K | 1.05M | +5% | $0 | |
| 2022-07-05 | 2022-07-05 | VRCA | Verrica Pharmaceuticals Inc. | Stalfort John A III | Dir | P - Purchase | $2.10 | +238.1K | 700.2K | +52% | +$500.0K | |
| D | 2021-07-08 | 2021-07-06 | ABOS | Acumen Pharmaceuticals, Inc. | Stalfort John A III | Dir | C - Cnv Deriv | — | +130.2K | 137.3K | +1,822% | — |
| DI | 2021-07-08 | 2021-07-06 | ABOS | Acumen Pharmaceuticals, Inc. | Stalfort John A III | Dir | C - Cnv Deriv | — | +131.6K | 131.6K | New | — |
| D | 2021-07-08 | 2021-07-06 | ABOS | Acumen Pharmaceuticals, Inc. | Stalfort John A III | Dir | P - Purchase | $16.00 | +35.0K | 172.3K | +25% | +$560.0K |
Purchase Sale Sale after option exercise All abbreviations